Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AMPENASDAQ:GRTXNASDAQ:ITRMNASDAQ:TRVN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.82+1.2%$1.68$0.70▼$8.30$681K2179,956 shs94,796 shsGRTXGalera Therapeutics$0.15-16.3%$0.20$0.09▼$3.59$8.35M2.232.09 million shs2.37 million shsITRMIterum Therapeutics$1.59+1.9%$1.55$0.62▼$2.50$20.96M2.35619,632 shs144,483 shsTRVNTrevena$0.46+4.6%$0.58$0.41▼$3.28$8.40M1.13112,014 shs68,134 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals+1.05%-49.38%-56.15%-65.25%-84.23%GRTXGalera Therapeutics-16.58%-36.70%-20.05%+7.34%-94.12%ITRMIterum Therapeutics+1.92%+0.63%+24.22%-20.50%+67.37%TRVNTrevena+3.45%-13.46%-19.97%-35.31%-39.15%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.3951 of 5 stars3.52.00.00.02.30.00.6TRVNTrevena2.6957 of 5 stars3.55.00.00.01.80.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio PharmaceuticalsN/AN/AN/AN/AGRTXGalera Therapeutics1.75ReduceN/AN/AITRMIterum Therapeutics3.00Buy$6.00277.36% UpsideTRVNTrevena3.00Buy$5.501,099.30% UpsideCurrent Analyst RatingsLatest TRVN, GRTX, AMPE, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$15.62 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($3.83) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A$2.29 per shareN/ATRVNTrevena$570K14.74N/AN/A$2.25 per share0.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$16.34M-$12.13N/A∞N/AN/A-111.36%-85.59%5/6/2024 (Estimated)GRTXGalera Therapeutics-$62.22M-$1.89N/A∞N/AN/AN/A-146.85%N/AITRMIterum Therapeutics-$44.43M-$2.44N/AN/AN/AN/A-216.28%-57.67%3/28/2024 (Confirmed)TRVNTrevena-$53.67M-$2.80N/AN/AN/AN/A-314.87%-71.98%4/4/2024 (Estimated)Latest TRVN, GRTX, AMPE, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AITRMIterum Therapeutics-$1.02N/A+$1.02N/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/A3.373.37GRTXGalera TherapeuticsN/A2.472.47ITRMIterum Therapeutics3.632.352.35TRVNTrevena8.356.416.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%GRTXGalera Therapeutics50.77%ITRMIterum Therapeutics9.21%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%GRTXGalera Therapeutics6.90%ITRMIterum Therapeutics5.40%TRVNTrevena2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals5830,000805,000No DataGRTXGalera Therapeutics3154.39 million50.64 millionOptionableITRMIterum Therapeutics1413.44 million12.71 millionNot OptionableTRVNTrevena3518.32 million17.88 millionOptionableTRVN, GRTX, AMPE, and ITRM HeadlinesSourceHeadlineTrevena files patent for treatment of acute respiratory distress syndrome using specific peptidespharmaceutical-technology.com - March 22 at 9:37 PMTrevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 21 at 2:20 AMTrevena Cross cafe reopening as the Palm Tree Bistromsn.com - March 16 at 3:06 PMTrevena Cross Garden Centre, The Palm Tree Bistrofalmouthpacket.co.uk - March 14 at 1:26 PMThe Palm Tree Bistro at Trevena Cross Nurseries reopeningmsn.com - March 8 at 10:03 AMTrevena Stock (NASDAQ:TRVN), Short Interest Reportbenzinga.com - February 22 at 1:18 PMTrevena files to sell 2.78M shares for holdersmsn.com - January 10 at 7:29 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 8:45 PMTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 28 at 3:44 PMTrevena announces private placement and warrant exercisemsn.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisemarkets.businessinsider.com - December 27 at 1:16 PMTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercisefinance.yahoo.com - December 27 at 1:16 PMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’msn.com - December 16 at 1:50 AMFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'msn.com - December 15 at 8:50 PMTrevena Awarded OLINVYK Agreement with Premier, Inc.finance.yahoo.com - December 4 at 8:26 AMTrevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meetingfinance.yahoo.com - December 4 at 8:26 AMTrevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuriesfinance.yahoo.com - November 30 at 9:45 AMTrevena Cross Garden Centre Breage new cafe jungle themefalmouthpacket.co.uk - November 19 at 7:48 AMTrevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - November 17 at 8:49 AMTrevena: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibitscbonds.com - November 16 at 7:20 AMTrevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 15 at 8:24 PMTrevena, Inc.: Trevena Reports Third Quarter 2023 Results and Provides Business Updatefinanznachrichten.de - November 14 at 1:33 PMTrevena Reports Third Quarter 2023 Results and Provides Business Updatemarkets.businessinsider.com - November 14 at 8:32 AMTrevena to Release Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 9 at 8:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks 3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option Activity3 Stocks About to Boom on Unusual Call Option VolumeMarch 18, 2024 8:46 AMView 3 Stocks About to Boom on Unusual Call Option VolumeMarketBeat Week in Review – 3/11 – 3/15March 16, 2024 7:00 AMView MarketBeat Week in Review – 3/11 – 3/15All Headlines Company DescriptionsAmpio PharmaceuticalsNYSE:AMPEAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.